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longitudinal positioning error (LPE) 
magnetic resonance imaging (MRI) 
hospital stay (LOS) 
intrahepatic cholangiocarcinoma (ICC) 
nonalcoholic steatohepatitis (NASH) 
radiofrequency ablation (RFA) 
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Abstract 
Background & Aims: 
Ablation plays an important role in the treatment of hepatocellular carcinoma. Because image-
guided navigation technology has recently entered the clinical setting, we aimed to analyze its 
safety, therapeutic and procedural efficiency. 
Methods: 
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Retrospective analysis of patients treated with stereotactic image-guided microwave ablation 
between 01/2015 and 12/2017. Interventions were performed using computertomography-
guidance with needle trajectory, ablation planning and automatic single-marker patient 
registration. Needle placement and ablation coverage was controlled by image fusion under 
general anesthesia with jet-ventilation.  
Results: 
In total 174 ablations were performed in 88 patients during 119 interventions. Mean age was 
66 (46-84) years, 74 (84.1%) were men and 74% were Child Pugh Class A. Median tumor size 
was 16 (4-45) mm, 62.2% were BCLC A. Median lateral and longitudinal error of needle 
placement were 3.2 (0.2-14.1) and 1.6 (0-15.8) mm. Median one tumor (1-4) was ablated per 
session. One patient developed a Dindo IIIb (0.8%) complication, 6 minor complications. After 
re-ablation of 12 lesions, an efficacy rate of 96.3% was achieved. Local tumor progression was 
6.3% (11/174). Close proximity to major vessels was significantly correlated with local tumor 
progression (p<0.05). Median overall follow-up was 17.5 months after intervention and 24 
months after initial diagnosis. BCLC stage, child class and previous treatment were significantly 
correlated with overall survival (p<0.05).  
Conclusion: 
Stereotactic image-guided microwave ablation is a safe and efficient treatment for HCC offering 
a curative treatment approach in general and in particular for lesions not detectable on 
conventional imaging or untreatable due to difficult anatomic locations.  
 
Key words: navigation, stereotactic, microwave ablation, hepatocellular carcinoma. 
 
Lay Summary / Key Points:  
Computer navigated minimal-invasive thermal ablation of hepatocellular carcinoma is a novel 
technique that allows a safe and efficient curative treatment in particular for inoperable, not 
detectable or conventionally unablatable liver lesions.  
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Introduction  
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death and 
the main cause of death in patients with cirrhosis 1.  Curative treatment options for patients 
with early stage HCC include surgical resection, orthotopic liver transplantation (OLT) and local 
ablation 2. However, only a minority of patients qualify for a curative treatments due to 
advanced liver disease, intrahepatic tumor distribution or comorbidities 3. Even potentially 
“ideal” transplant candidates may not go on to have the surgery they would actually require, 
with many transplant centers rarely adopting OLT as a first-line option for very early or early 
HCC 4. Furthermore, as resection or ablation do not preclude salvage OLT in case of treatment 
failure, the use of initially less invasive strategies is often favored 5, 6. Indeed, with 5-year overall 
survival rates of up to 75 %, ablation has been validated as an alternative to resection for very 
small tumors (Barcelona Clinic Liver Cancer classification (BCLC) stage 0)7 and patients with 
limited disease non-resectable due to associated liver disease (BCLC stage A)8. In addition, 
ablation has shown promising results within combination therapies for advanced disease 9, 10 
and is commonly used as bridging to OLT (as recommended by the current AASLD and EASL 
guidelines) 11-13. The major advantage of ablation lies in its minimal-invasive tissue-sparing yet 
locally destructive character, with short hospital stays and low morbidity 14. Although 
radiofrequency ablation (RFA) is used mostly for HCC, microwave ablation (MWA) has recently 
entered the clinical field and is now increasingly used due to shorter ablation times, a potential 
advantage for larger tumors and reduced heat sink effect, which occurs when hepatic blood flow 
reduces the local heat distribution by its cooling effect 15. 
Next to tumor burden and the extent of the underlying liver disease, initial complete response 
represents an independent predictive factor for recurrence-free and disease-specific survival in 
patients undergoing ablation for HCC 16. Hence, the precision of  ablation might represent a 
crucial factor for treatment success, relying directly on optimal visualization of intrahepatic 
lesions and accurate placement of ablation probes within the tumor targets. To optimize 
guidance of the ablation probe and thus precision in tumor targeting and ablation, advanced 
stereotactic navigation technology has been introduced, and several navigation systems are 
now available for image-guided interventions 17-19. First reports on stereotactic percutaneous 
computed tomography (CT) - guided ablation of liver tumors have been published, suggesting a 
safe and accurate treatment 20-22. While a few works report oncological benefits when using 
stereotactic ablation for colorectal liver metastases 23, no data exists on oncologic outcomes 
after stereotactic CT-guided microwave ablation in a large cohort of HCC patients.  Furthermore, 
difficult to detect  lesions in ultrasound or CT and potentially inaccessible lesions are usually not 
taken into account in studies reporting HCC ablation results. Hence, understanding the clinical 
impact of using novel navigation technology for image-guided ablation of HCC remains scarce.  
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Overall, we hypothesize that stereotactic image-guided microwave ablation (SMWA) is a safe 
and precise ablative treatment for all HCCs including those lesions that are conventionally 
ineligible to ablation (difficult anatomical location / not detectable on ultrasound or CT) or 
inoperable due to the underlying liver disease or patient comorbidities. In this first 
retrospective analysis, we report safety and therapeutic efficacy in terms of local tumor control 
and short-term survival, as well as procedural efficiency in terms of targeting accuracy and 
required time when using SMWA for the treatment of HCC.  
 
 
Materials and Methods 
All patients with HCC treated with SMWA at the Department of Visceral Surgery and Medicine 
and the Department of Radiology, University Hospital of Bern, Switzerland between January 
2015 and December 2017 were retrospectively included in the analysis. The study protocol was 
approved by the Regional Ethical Review Board (KEK-No. 2017-01038), and registered at 
clinicaltrials.gov (NCT03630068).  
 
Patient population 
All patients were discussed in the institutional multidisciplinary tumor board. General 
indications for SMWA included patients with 1) single solitary lesions <2cm (BCLC 0), 2) single 
or up to 3 nodules  ≤ 3cm (BCLC A) not amenable to resection or OLT, 3) multinodular disease 
and/or tumors >3cm (BCLC B) whenever the tumor board agreed to perform a downstaging so 
that patients could be evaluated for liver transplantation 24. Accordingly, SMWA was the method 
of choice as a bridge-to-transplant or as a downstaging procedure for patients awaiting OLT.  
SMWA is also the standard of care for all patients receiving an ablative treatment of HCC at our 
institution irrespective of the tumor location. Tumors had to be radiologically (using the LIRADS 
categorical system) 25 or histologically confirmed HCC requiring SMWA as indicated by the 
consensus tumor board decision. Written informed consent was obtained before the procedure 
in patients aged ≥ 18 years. 
 
Procedural technique 
All procedures were performed under general anesthesia in the interventional CT suite by an 
interdisciplinary team consisting of specifically trained surgeons and interventional 
radiologists. Patients were placed on the CT table and High Frequency Jet ventilation was used 
to ensure minimal movement of the patient and the diaphragm during the procedure. The 
intervention always consisted of four main procedural steps: (1) planning, (2) navigation, (3) 
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probe validation and ablation, (4) ablation zone validation (Figure 1). At first, a CT planning 
scan was performed (SOMATOM Definition Flash, Siemens Healthineers, Erlangen, Germany) 
using a predefined multi-phase imaging protocol (2 x 64 x 0.6 mm; 280 msec gantry rotation 
time; pitch factor, 0.6; tube voltage; 100 kV) after the application of intravenous contrast 
medium (100-120 mL Ultravist® (volume depending on body mass of patients), Bayer 
Healthcare, Berlin, Germany) using bolus tracking (threshold 100 HU) for starting the scan: 
arterial phase 8 seconds after reaching the threshold, portal venous phase after another 25 
seconds, and a late phase after another 150 seconds. The scan lengths was adapted to the size 
and height of the patients always including 6 fiducial markers attached to the patients’ skin 
surface. The radiologist in the team reviewed all three CT phases to choose the scan in which 
the target lesion(s) was (were) best detectable. This scan was transferred to a commercially 
available navigation system (CAS-ONE, CAScination AG, Bern, Switzerland) which was then used 
for trajectory planning. After positioning of the ablation probe in the target lesion in the liver, a 
non-enhanced CT scan was performed to validate the correct positioning. The accuracy of 
needle placement with respect to the planned target point was evaluated by a fusion of the 
planning image with the needle control scan. The navigation system provides functionality for 
automatic image fusion, automatic needle detection and for calculation of lateral and 
longitudinal errors (distance between the active zone of the needle and the needle target point 
in the tumor. Thermal ablation of up to four lesions per patient was performed using microwave 
probes (Acculis MTA System, AngioDynamics, Latham, NY, USA). Finally, a contrast enhanced CT 
scan with three phases was performed in the same way as the planning scan to allow an 
immediate treatment validation of all target lesions by fusing both scans. The navigation system 
automatically performs a fusion between the planning and validation scan and allows for 
margin assessment by projecting the tumor segmentation from the planning image onto the 
validation scan. Further evaluation can be performed by image overlay where the planning and 
validation scans are displayed simultaneously and the user can switch back and forth between 
the images. This  50/50% display was frequently used to  estimate if the planned safety margin 
was obtained. A safety margin of 0.5-1 cm was anticipated. If the validation showed an 
insufficient safety margin, a re-ablation was planned covering the area of the insufficient 
margin. The validation scan with the ablation zone could be fused with the pre-interventional 
scan to directly target the insufficiently ablated area. 
 
Data extraction and assessment 
Demographic and clinical data were extracted from patient’s medical records. Lesion-specific 
and radiological data were extracted from DICOM imaging files, and technical data acquired 
during the intervention was extracted from the navigation system log files.  
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To evaluate technical and procedural efficiency of SMWA, targeting accuracy assessed as lateral 
and longitudinal positioning error (LPE), time efforts required for the four procedural steps and 
overall duration of the procedure were measured.  90-day clinical and radiological 
complications were collected and graded according to the Dindo-Clavien classification 26. The 
first follow-up imaging (magnetic resonance imaging (MRI) or CT) was carried out routinely 1-3 
months post-treatment, with re-imaging every 3 months in case of stable disease. When MRI 
was performed, a specific liver imaging protocol was used including the hepatocyte-specific 
contrast medium gadoxetic acid (Primovist™/ Eovist™, Bayer Healthcare Pharmaceuticals, 
Berlin, Germany). Technique efficacy was reported according to the standardized criteria 
suggested by Ahmed et al. 27, and 1) tumors showed no signs of residual tumor within 10 mm 
from the edge of the ablation zone on the first follow-up imaging (1-3 months post-
interventional) or 2) tumors with residual tumor on the first follow-up scan were successfully 
re-ablated within 6 months. Local tumor progression was defined as the presence of detectable 
tumor within 10 mm from the edge of the ablation zone or the resection site on follow-up 
imaging after at least one prior follow-up imaging showed no residual tumor at the ablation 
zone/resection site. Disease progression was analyzed as either local tumor progression at the 
ablation zone, disease progression in the liver showing new liver lesions outside the ablated 
region and overall disease progression including distant metastases. Imaging results were 
interpreted and verified by two independent radiologists. The appearance of new intrahepatic 
or extrahepatic lesions was also documented. Transplantation was considered as a censored 
event for the survival analysis. 
 
Statistics 
Descriptive statistics were used for presentation of patient characteristics and outcome data. 
Continuous data are shown as mean and standard deviation or median and range where 
appropriate. The student T-Test was used to evaluate possible differences between groups. The 
Kaplan-Meier method, log rank test, logistic regression and cox regressions were applied to 
analyze the association of variables with local tumor progression, progression-free and overall 
survival. The threshold for statistical significance was set to p≤0.05. Descriptive statistics and 
graphs were analyzed using SPSS Version 25. 
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Results 
 
Clinical Data 
Over a period of 36 months, 88, predominantly male patients were treated for 174 lesions in a 
total of 119 SMWA interventions at our institution (Table 1). Half of the patients (n=44) had 
previously been treated for HCC by other means (Table 1). Sixteen (36.4%) of these SMWA 
treated lesions were local tumor progressions after previous treatment failure, 28 (63.6%) were 
new tumors located elsewhere in the liver. In 33 patients, SMWA was performed as a bridging 
procedure prior to liver transplantation.  
Ninety-nine (83.2%) interventions were performed in cirrhotic livers, 13 (10.9%) in  fibrotic 
liver, for seven (5.9%) interventions the degree of underlying liver disease was unknown. 
 
HCC-specific data 
At the time of intervention the majority of patients were BCLC stage A (n=74, 62.2%) (Table 1). 
Treated lesions were located in all liver segments, including segment I (Figure 2). The majority 
of tumors were located in segment VIII (32.2%), followed by a relatively even distribution of 
lesions in all other segments. While more than half of the treated lesions (59.2%) were localized 
subcapsular (within 10mm), 29.9 % were in close proximity (within 5mm) to major blood 
vessels (> 3mm). Among these, 32 lesions were located close to a portal vein branch, 11 close to 
a liver vein, one close to the vena cave and three close to the hepatic artery. Forty-five (25.9%) 
lesions were within 10 mm of the diaphragm or heart. Eleven lesions were in close proximity to 
other organs including the gallbladder (n=4), kidney (n=2), duodenum (n=1), stomach (n=2) 
and colon (n=2) (Figure 2).   
 
Intervention-specific data 
The majority of patients had one (n=77, 64%) or two (n=31, 26.1%) tumors treated during one 
intervention. Nine patients had three (7.6%) and two patients had four (1.7%) lesions ablated 
during one intervention. All interventions were performed with microwave energy between 60 
and 140 Watt for a median of five (1:30-18) minutes per tumor (Table 2). Thirteen lesions were 
treated with two needles and four lesions with three parallel needles to achieve overlapping 
ablation zones. We treated tumors > 3cm significantly more often with multiple needles 
(66.7%) than smaller lesions (33.3%), (p>0.005, Chi square test). For further technical details, 
see Table 2.  The control of the ablation zone revealed an insufficient margin for 26 lesions 
immediately post-ablation, 19 of which could be immediately re-ablated. Three lesions could 
not be re-treated due to close proximity of the region of a potential insufficient margin to a 
major blood vessel (n=1), gallbladder (n=1), or lung (n=1). One lesion was ablated to prepare a 
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contralateral hepatectomy and three lesions were planned for an early follow-up. For 13 
interventions, post-interventional imaging showed small intrahepatic or subcapsular 
hematomas and after one procedure a small pneumothorax was detected. None of these 
radiological findings were clinically symptomatic and they did not require any further 
treatment or follow-up. These incidental findings due to the detailed post-ablation scan were 
therefore not considered complications.  
 
Post-interventional Data 
Median length of hospital stay (LOS) after the intervention was two (range 1 - 4) days. The 
overall 90-day complication rate was 5.9% (7/119), with six grade I-IIIa and one grade IIIb 
complication (Table 3). Grade I-IIIa complications included two ascites decompensations, one 
pleural effusion and one pneumothorax requiring drainage, one patient with post-
interventional pain exacerbation and one patient with post-interventional fever treated with 
antibiotics. The patient with the Dindo grade IIIb complication required surgery for a suspected 
abscess (diagnosed on radiological imaging and fever), which was proven neither histologically 
nor in microbiology tests and probably represented a case of post ablation syndrome with fever. 
While we did not observe significant changes in the hemoglobin and creatinine levels before 
and after the intervention, the alanine transaminase increased significantly from a median 38 
U/l to  90 U/l (p = 0.000) without any clinical correlation. This increase was not considered a 
pathological finding as it reflects the destruction of liver tissue through ablation. 
 
 
Local tumor control and short-term survival 
The overall rate of residual tumor per lesion after the first intervention was 12.1% (21/174) at 
a 1-3 months follow-up. Of these, 12 (6.9%) were successfully re-ablated in a second 
intervention within 6 months of the initial treatment, resulting in an efficacy rate of 96.3% 
(165/174).  Nine lesions (5.2 %) with residual tumor at 1-3 follow-up received no additional 
ablation for varying reasons: two lesions turned out to be an intrahepatic cholangiocarcinoma 
(ICC) (among other HCC lesions in a nonalcoholic steatohepatits (NASH) liver) and a mixed 
HCC/ICC (among other HCC lesions), respectively, and treatment was switched to systemic 
therapy. Two patients were planned for re-ablation but were transplanted just prior to 
receiving their SMWA, two patients were treated by laparoscopic ablation and resection, 
respectively, two patients had progressive disease and treatment was switched to systemic 
therapy, one patient was lost to follow-up.  Eleven lesions (6.3%) developed a local tumor 
progression after 6 months of follow-up and at least one local tumor progression-free imaging. 
While nine (5.7%) of these lesions were successfully re-ablated, one patient was transplanted 
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before a re-ablation could be performed and one patient showed additional new intrahepatic 
lesions requiring a change to systemic therapy. 
Close proximity to a major blood vessel (p=0.014) was the only factor significantly correlated 
with local tumor progression in the logistic regression analysis (Table 4). Tumor size ≥ 3 cm 
showed a trend to an inverse correlation with recurrence. 
 
In the time to local tumor progression analysis (Figure 3A) tumor size > 3cm (log rank test 
p=0.015 95% CI: 2.359-18.641) was significantly correlated with local tumor progression-free 
survival. 
Overall median follow-up from the intervention to death or end of follow-up was 17.25 (1.4-
48.1) months, and 24 (1.4-127.8) months from initial diagnosis to death or end of follow-up. 
Follow-up ended at the time of transplantation. Twenty-five (28.4%) patients died during this 
follow-up period, 17 (19.3%) due to tumor progression (14 with HCC, one patient developed an 
acute myeloid leucemia, one patient a renal cell cancer and one patient developed an 
intrahepatic cholangiocarcinoma). Four patients died due to decompensated cirrhosis, three 
due to septic complications not related to the intervention and for one patient, cause of death 
remained unknown. 
BCLC stage, child class and previous treatment within the last 2 years before SMWA were 
significantly correlated with survival /drop-out due to OLT in the univariate analysis (Figure 
3B-D) and remained significant in the multivariate analysis (Supplementary Table 1). 
 
SMWA as bridging therapy 
Thirty-three (37.5%) patients awaiting transplantation underwent SMWA as a bridging 
procedure. Out of these patients, 22 were transplanted after a median time of 10.7 (1.1 – 25.4) 
months, having undergone a median of one (1 - 4) SMWA treatment. Thirteen (65%) had 
combined bridging treatments (five SMWA and TA(C)E, 6 SMWA and resection, 2 SMWA and 
laparoscopic ablation). Eleven patients dropped out of the waiting list. This included disease 
progression outside Milan criteria (n=6), development of other cancers (n=3) and other reasons 
(n=2). All transplanted patients remain alive to date after a median follow-up of 7.1 (0-24.2) 
months post-transplant. Analysis of 40 ablation zones in the 22 explanted livers showed 
complete necrosis in 26/40 (65%) treated lesions with a mean rate of necrosis of 87% (15-100) 
(Figure 4). 
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Discussion 
In this large retrospective analysis, we report our experience with stereotactic-image-guided 
microwave ablation of HCC and show that SMWA is a safe and efficient minimally invasive 
treatment option achieving good oncological outcome and local tumor control. 
Current guidelines still recommend RFA as the standard of care for the percutaneous treatment 
of HCC based on good local tumor control, with local recurrence rates between 3.2 and 28.5% at 
3 years and an overall survival between 60 and 84.1% at 3 years 28. This relatively large 
variation in local recurrence rates might be explained by the use of different technical devices, 
differences in image-guidance and also by not applying a uniform terminology for what is meant 
by local recurrence in particular with respect to the development of new intrahepatic lesions. A 
possible large variation of technical success rates among different centers might also be the 
reason, which is why a recent publication stated that ablation is correlated with worse overall 
survival compared with resection 29.   
More recently, RFA was challenged by MWA, which allows for faster treatment of larger tumors 
with greatly reduced heat-sink effect, a process that describes a decrease in local efficacy due to 
the cooling effect of blood flow in major vessels in proximity of the lesion to be ablated 30. 
However, data on large patient series comparing both approaches are still rare. Nevertheless, 
MWA is increasingly being used for the percutaneous treatment of HCC with reported local 
tumor progression rates between 3.9-17% and an overall survival between 49 and 86.1% 28. A 
recent meta-analysis by Luo et al. demonstrated similar rates of local tumor control and overall 
survival when MWA and RFA were compared, with a slight benefit for MWA for the treatment of 
tumors larger than 3 cm 31. 
 
 
The treatment algorithm for HCC is highly complex and even though the BCLC classification is 
widely accepted, centers often decide differently for their patients in the “real life” setting. This 
is partly due to differences in organ availability and allocation, but mostly due to the 
complicated interplay of the degree of the underlying liver disease, the extent of relevant co-
morbidities, the anatomical location of the tumor and the on-site clinical / interventional 
expertise and the availability of modern technology allowing minimally invasive treatment 
approaches. All this makes the design of prospective trials almost impossible and explains the 
tremendous selection bias in most of the retrospective analyses in this field. Several studies 
suggest that up to a third of patients with early HCC end up receiving palliative therapies, rather 
than undergoing a curative approach as recommended for patients with early disease stages 32, 
33. This might in part be attributed to tumor location, such that patients with “difficult to reach” 
lesions or those not detectable on ultrasound or CT end up being placed in the palliative 
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treatment group instead. In addition, most transplant candidates with BCLC A will not receive 
an up-front transplantation and thus need to be bridged with the most effective local treatments 
available. 
Even though ablation may be considered as a minimally invasive procedure in itself, its 
feasibility is highly dependent on tumor visibility and the exact anatomical location of the lesion 
within the liver. It is known that up to a third of lesions remain “unablatable” in the clinical 
setting due to tumor location (proximity to critical structures), failure to detect the lesion on 
ultrasound or CT and high risk patients unsuitable for the intervention 34. With this in mind, 
navigation technology has entered the field of hepatobiliary surgery and interventional 
radiology, allowing pre-interventional planning, precise navigated targeting and validation for 
immediate control of the treatment success. In our patient series, all patients suggested for 
microwave ablation therapy as agreed upon in our multidisciplinary tumor board, received 
SMWA, even if some lesions might have been ablatable by the conventional free-hand and 
ultrasound-guided approach (see also figure 2 for details). Indeed, the majority of our patients 
had tumors located in difficult to treat areas (close proximity to large vessels and/or bile ducts, 
sub-diaphragmatic lesions or subcapsular locations close to adjacent organs) and did not need 
additional supportive techniques such as hydro dissection using artificial ascites to overcome 
anatomical problems and to place the ablation probe 35, 36. Our high precision of needle 
placement is further reflected by the low mean lateral and longitudinal error of 3.2 and 1.6 mm 
and the fact that almost no needle replacements were necessary in our cohort. Few cases with 
relatively high lateral and longitudinal errors received no replacement of the ablation probe 
because the corrected simulated ablation zone for the deviated probe was still sufficiently 
covering the lesion or because the interventionalist preferred to ablate any resulting insufficient 
margin after performing the validation scan. The geometrical accuracy of 3.2 mm median lateral 
error achieved with CAS-One IR navigation system is comparable to similar navigation 
approaches in the literature. The group in Innsbruck reports lateral errors of 3.6 ±2.5 mm in a 
series of 145 needle placements on 20 patients using an optical navigation system 37. Users of a 
robotic navigation system report applicator active point deviation after the first needle 
insertion of 5.3 ±1.8 mm 38 and 3.1 ±2.5 mm 39 for series of 21 resp. 34 patients. In both reports, 
manual repositioning of the needle was performed and led to final positioning errors of 1.9 ±1.7 
mm resp. 1.6 ±1.3 mm. A randomized study on computer assisted electromagnetic navigation 
shows a median initial targeting accuracy of 4.1 mm for 60 needle placements 40. In this study 
too, further needle corrections where performed manually after the initial navigated needle 
placement. Comparing these results, we see that our results of 3.2 mm lie within the range of 3.1 
to 5.3 mm reported in literature. Given, the high unpredictability of ablation zones with a given 
power/time setting 41, we see the ablation validation using a post-ablation control scan as a 
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crucial step for obtaining reliable tumor control in one session. In our treatment algorithm, the 
ablation prediction (based on manufacturer’s datasheets) is used as an estimate for the 
required ablation energy. Independent of this prediction, we always use the navigation software 
to fuse pre- and post-ablation images in order to reliably validate the achieved ablation zone 
and trigger a re-ablation in the same session when insufficient margins are observed. A further 
aspect in standardizing ablation treatment is the use of JET-ventilation which guarantees 
minimal breathing movements that are required to achieve the precise placement of probes. 
Overall, our highly standardized protocol with reproducible workflows probably contributes to 
our low intra- and post-interventional complication rates.  Although many argue that using 
general anesthesia and computer navigation for liver ablation leads to prolonged intervention 
times, there is not much data supporting this assumption. Indeed, Beyer et al.  showed that 
procedure times were not increased when using SMWA for liver tumor ablation 42. With the help 
of navigation technology, all patients in our cohort successfully underwent SMWA, even though 
in some instances a fusion with the pre-interventional MRI image had to be performed to 
visualize the lesions. So-called “invisible” lesions or lesions in the sub centimeter range were 
therefore no hindrance for treatment, a problem that is commonly described in US- (and CT-) 
guided ablations. Tumor seeding could be avoided in all cases due to the exact planning of the 
needle insertion site and needle tract ablation.  
Although it has been widely published that complication rates after local ablation are 
significantly reduced compared to local resection 43, 44, data is limited on patients treated with 
SMWA. Our patient series shows a very low complication rate compared to most of the 
literature, accompanied by a short hospital stay with quick recovery. Engstrand et al. using the 
same navigation system for liver ablations also recently reported similar results 21. 
Even though the focus of our retrospective analysis was safety, and local efficacy of SMWA, 
short-term survival analyses showed that BCLC stage B, Child class and previous HCC treatment 
were significantly correlated with poor outcome. Our cohort reflects the fact that patients often 
receive multiple different and personalized treatments in the course of the disease hampering 
clear survival analyses of ablated HCC lesions. As previously reported, tumor size was 
significantly correlated with the development of local tumor progression. This might simply be 
due to the limitations of tissue destruction by microwave energy and future studies clearly need 
to show if new multi-probe ablation systems creating overlapping ablation zones will help to 
overcome this problem 22. While we were able to see worse local tumor-progression-free 
survival in patients treated for HCCs > 3cm, we could not detect tumor size as a predictor of 
local tumor progression. In our cohort, most tumors with this size were treated with multiple 
parallel needles, eventually explaining our observation of even a trend towards an inverse 
correlation. 
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 In our view, the underlying degree of liver disease with its varying degree of liver stiffness 
might influence the size of the ablation zone and ultimately the treatment success. More 
detailed analyses of the underlying liver disease might help to develop predictors for local 
tumor progression and recurrence and to accurately plan ablation power and time with respect 
to the degree of steatosis, fibrosis or cirrhosis. Due to the retrospective nature of this study, the 
local tumor control rate and the overall survival rate could not be compared to another 
conventional treatment in our cohort. According to our treatment algorithm, SMWA is 
recommended for all BCLC 0 and A patients and for unresectable BCLC B patients either as a 
downstaging before OLT or in a curative intent whenever overlapping ablations zones can 
achieve a technical success with sufficient margins. 
Many (>37%) of our patients received SMWA as a bridging therapy to transplant. With average 
waiting times in Switzerland currently being around 12 months (www.swisstransplant.org), our 
aim was to use a potentially curative approach, with as many candidates as possible achieving 
complete pathological response (as documented in the explant) and as low as possible waiting 
list drop-out rates due to tumor progression. While our retrospective analysis of the explant`s 
H&E histology report only used the estimation of the pathologist (mean rate of necrosis 87%), a 
recent paper by Bale et al. showed a complete pathological response of 97.3% when explants 
were analyzed by H&E and an apoptosis assay, because it had been shown earlier that 
conventional H&E staining underestimates the degree of necrosis 45. With this in mind, we 
assume to achieve similar success rates with our technique. 
Cancer treatment has changed dramatically over the last few years, with “one therapy fits all” 
regimes being replaced by patient-tailored, individualized strategies for a variety of cancers 
including HCC. Hereby, interventions, treatments, or other medical decisions are specifically 
designed for the individual patient, based on their predicted response or risk of disease 46. 
Increasingly, patients with advanced age and concomitant comorbidities but limited disease are 
also being put forward for oncological treatments with curative intent. This patient population 
particularly profits from locally effective, but low risk,  tissue-sparing interventions, where 
repeat therapy sessions are well tolerated even in case of local tumor progression [10,11]. In 
conclusion, SMWA using a computer-assisted navigation system is a safe and locally effective 
procedure for patients with HCC. While it improves the eligibility to a potentially curative and 
minimally invasive treatment option for patients conventionally unablatable it also represents a 
promising treatment alternative for lesions unresectable due to patient and liver comorbidity. 
Highly standardized treatment protocols as well as a specifically dedicated team, put together of 
hepatobiliary surgeons as well as interventional radiologists, ensure procedural safety while 
maximizing oncological outcome. 
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Figure legends 
 
Figure 1. Work-Flow of SMWA showing (A) Planning phase: planning and simulation of the 
ablation probe trajectory. The target tumor (red circle) can be segmented automatically or 
manually, the expected ablation zone (green circle) is simulated according to the energy and 
time that will be applied. (B) Navigation phase: navigated positioning of ablation probe. The 
aiming device ensures stability and guides the insertion of the probe. (C) The computer 
calculates the required length of the inserted ablation probe. (D, E) Probe validation and 
ablation phase: validation of the intrahepatic ablation probe position followed by ablative 
treatment. If necessary the probe can be retracted or further inserted according to the 
calculations of the navigation system. (F) Ablation zone validation phase: overlay of pre- and 
post-ablation images in order to determine the safety margin and to plan another ablation if 
necessary.  
 
Figure 2. (A) Distribution of treated lesions in the liver in relation to liver segments, (B) 
distribution of difficult-to-treat lesions in relation to their neighboring anatomic structures. 
 
Figure 3. Kaplan-Meier curves showing local tumor progression-free survival (A) correlated 
with tumor size ≥ 3 cm, and overall survival (B-D) correlated with (B) BCLC stage, (C) Child 
class and (D) previous HCC treatment.  
 
Figure 4. (A) Explanted liver with several SMWA-treated lesions, one opened to demonstrate 
the necrosis, (B) HE-staining of ablation zone showing complete necrosis. 
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